Lung Cancer

Lung Cancer

SS 26 - Lung 3 - Toxicity

10/23/2018
2:45 PM - 4:15 PM
Location: Room 007 C/D

Session Type: Scientific
1.50 AMA PRA Category 1 Credits™
1.50 CAMPEP Credits

Presentations:

Maria Werner-Wasik, MD, FASTRO

Thomas Jefferson University

Disclosure:
Employment
Thomas Jefferson University: Professor: Employee

Ownership
Illumina: Stock

Leadership
Jefferson Health: Enterprise Vice-Chair for Radiation Oncology

Biography:
Maria Werner-Wasik, MD, FASTRO, is Walter W. Curran Professor of Radiation Oncology at the Sidney Kimmel Medical College of Thomas Jefferson University and Enterprise Vice-Chair for Radiation Oncology at Jefferson Health. She is also the Contact Principal Investigator for NRG Oncology at Jefferson. Dr. Werner-Wasik graduated from medical school in Wroclaw, Poland, and completed her postgraduate training in radiation oncology at Tufts/New England Medical Center in Boston and at the University of Pennsylvania in PHiladelphia. She frequently lectures on lung cancer at national and international conferences such as the American Society for Therapeutic Radiation Oncology (ASTRO), the American Society for Clinical Oncology (ASCO), and the International Association for the Study of Lung Cancer (IASLC) World Conference. She is ccurrently the Lung Track Leader for the annual scientific ASTRO meeting and serves as an American Board of Radiology core group Oral Examiner for the Radiation Oncology Specialty Board examination. She is a member of the RTOG/NRG Lung Cancer Steering Committee and was a Co-Chair or Chair of several RTOG lung and brain trials. Dr. Werner-Wasik has served as Publications Chair of the Radiation Therapy Oncology Group's (RTOG) and is member of the RTOG Foundation's Board, as well as Chair of the newly formed NRG Oncology Protocol Monitoring Committee (PMC). She has been awarded several "Best Doctor" titles (Philadelphia Top Doctor; America's Top Doctor for Cancer; America's Top Doctor, America’s Top Oncologist, Top 1% of Physicians in America) and has over 150 publications to her credit on topics of lung and brain cancers, as well as treatment-related toxicity. Currently she devotes her energies to the harmonization and integration efforts of all radiation oncology divisions within Jefferson Health. Maria Werner-Wasik is married, has two grown daughters and a toddler grandson.

Presentation(s):

Send Email for Maria Werner-Wasik

Clifford Robinson, MD

Siteman Cancer Center/Washington University School of Medicine in St. Louis

Disclosure:
Employment
Washington University in St Louis: Assistant Professor: Employee

Compensation
DFINE: Speaker's Bureau, Travel Expenses; Elekta: Research Grants; Radialogica: Advisory Board; Varian Medical Systems: Research Grants, Speaker's Bureau, Travel Expenses

Ownership
Radialogica: Stock Options

Biography:
Dr. Cliff Robinson an Associate Professor of Radiation Oncology at Washington University in St. Louis where he serves as Chief of the Stereotactic Body Radiation Therapy (SBRT) service, and Director of Clinical Trials and Clinical Informatics. An overreaching theme to his research interests are the development and optimization of advanced radiotherapy delivery, with a particular focus on integrating and testing these methods with other specialties through collaborative, multidisciplinary clinical trials.

In his work with cardiothoracic surgery, he is PI of a trial exploring outcomes after SBRT or surgery for early stage lung cancer, including development of patient selection models and piloting a bundled-payment model across the two disciplines. Through collaborations with medical oncology, he is a co-chair on multiple national cooperative group trials exploring the safety and efficacy of SBRT as a means to improve survival for metastatic cancer, and PI of an institutional trial testing the novel combination of immunotherapy with esophageal brachytherapy to enhance immune response in metastatic esophageal cancer.

In his most recent foray outside of cancer, he has partnered with cardiology in the development of a novel, totally noninvasive treatment for arrhythmia using SBRT. In this capacity, he is co-PI of a trial exploring the safety and preliminary efficacy of this treatment for high risk patients with refractory ventricular tachycardia.

Presentation(s):

Send Email for Clifford Robinson


Assets

SS 26 - Lung 3 - Toxicity



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for SS 26 - Lung 3 - Toxicity